0
Détail de l'éditeur
American Medical Association (AMA)
Collections rattachées :
|
Documents disponibles chez cet éditeur (19)
Ajouter le résultat dans votre panier Affiner la recherche
Prenatal and postnatal environmental tobacco smoke exposure and children's health / Joseph R. DiFranza (2004)
Titre : Prenatal and postnatal environmental tobacco smoke exposure and children's health Type de document : texte imprimé Auteurs : Joseph R. DiFranza, Auteur ; Andrew Aligne, Auteur ; Michael Weitzman, Auteur Mention d'édition : 113 Editeur : American Medical Association (AMA) Année de publication : 2004 Collection : JAMA Pediatrics num. 113 Importance : p.1007-1015 Langues : Anglais (eng) Catégories : [TABAC] tabagisme:risque:facteur associé:grossesse:foetus
[TABAC] tabagisme:tabagisme actif:tabagisme parental
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 7.4.2.1 chez l'enfant Résumé : Children's exposure to tobacco constituents during fetal development and via environmental tobacco smoke (ETS) exposure is perhaps the most ubiquitous and hazardous of children's environmental exposures. A large literature links both prenatal maternal smoking and children's ETS exposure to decreased lung growth and increased rates of respiratory tract infections, otitis media, and childhood asthma, with the severity of these problems increasing with increased exposure. Sudden infant death syndrome, behavioral problems, neurocognitive decrements, and increased rates of adolescent smoking also are associated with such exposures. Studies of each of these problems suggest independent effects of both pre- and postnatal exposure for each, with the respiratory risk associated with parental smoking seeming to be greatest during fetal development and the first several years of life. En ligne : https://pediatrics.aappublications.org/content/113/Supplement_3/1007.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8087 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults / Brian A. Primack (2015)
Titre : Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults Type de document : texte imprimé Auteurs : Brian A. Primack, Auteur ; Samir Soneji, Auteur ; Michael Stoolmiller, Auteur ; Michael J. Fine, Auteur ; James Sargent, Auteur Editeur : American Medical Association (AMA) Année de publication : 2015 Collection : JAMA Pediatrics num. 169(11) Importance : p.1018-1023 Langues : Français (fre) Catégories : [DIVERS] personne:par âge:jeune
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] tabagisme:risque:facteur associéIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Electronic cigarettes (e-cigarettes) may help smokers reduce the use of traditional combustible cigarettes. However, adolescents and young adults who have never smoked traditional cigarettes are now using e-cigarettes, and these individuals may be at risk for subsequent progression to traditional cigarette smoking. En ligne : https://jamanetwork.com/journals/jamapediatrics/fullarticle/2436539 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9101 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Recent advances in the pharmacotherapy of smoking / John R. Hughes (1999)
Titre : Recent advances in the pharmacotherapy of smoking Type de document : texte imprimé Auteurs : John R. Hughes, Auteur ; Michael G. Goldstein, Auteur ; Richard D. Hurt, Auteur ; Saul Shiffman, Auteur Editeur : American Medical Association (AMA) Année de publication : 1999 Collection : JAMA : Journal of the American Medical Association num. 281 (1) Importance : p.72-76 Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:pharmacologie
[TABAC] sevrage tabagique
[TABAC] tabagismeIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Since the 1996 publication of guidelines on smoking cessation from the Agency for Health Care Policy and Research and the American Psychiatric Association, several new treatments have become available, including nicotine nasal spray, nicotine inhaler, and bupropion hydrochloride. In addition, nicotine gum and patch have become available over-the-counter. This article reviews the published literature and US Food and Drug Administration and pharmaceutical company reports on these therapies. Based on this review, clinical logic, and experience, we conclude that pharmacotherapy should be made available to all smokers. All currently available therapies appear to be equally efficacious, approximately doubling the quit rate compared with placebo. Concomitant behavioral or supportive therapy increases quit rates and should be encouraged but not required. Combining patch with gum or patch with bupropion may increase the quit rate compared with any single treatment. Because patient characteristics predictive of success with a particular therapy are not yet known, the best treatment choice for an individual patient should be guided by the patient's past experience and preference and the product's adverse effect profile. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2588 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002334 TA 6.2.3. HUH R Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Risk of tuberculosis from exposure to tobacco smoke : a systematic review and meta-analysis Type de document : document électronique Auteurs : Michael N. Bates, Auteur Editeur : American Medical Association (AMA) Année de publication : 2007 Collection : Archives of internal medicine, ISSN 0003-9926 num. 167(4) Importance : p.335-342 Langues : Anglais (eng) Catégories : [TABAC] tabagisme:effet du tabac
[TABAC] tabagisme:pathologie:pathologie respiratoire:tuberculose
[TABAC] tabagisme:tabagisme actifIndex. décimale : TA 3.2.2.4 Pathologies respiratoires (sauf 3.2.2.1, 3.2.2.2, 3.2.2.3) Résumé : Background There is no consensus whether tobacco smoking increases risk of tuberculosis (TB) infection, disease, or mortality. Whether this is so has substantial implications for tobacco and TB control policies.
Objective To quantify the relationship between active tobacco smoking and TB infection, pulmonary disease, and mortality using meta-analytic methods.En ligne : https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/411801 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9952 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Smoking and smoking cessation in relation to mortality in women / Stacey A. Kenfield (7/05/2008)
Titre : Smoking and smoking cessation in relation to mortality in women Type de document : texte imprimé Auteurs : Stacey A. Kenfield, Auteur Editeur : American Medical Association (AMA) Année de publication : 7/05/2008 Collection : JAMA : Journal of the American Medical Association num. 299 (17) Importance : p.2037-2047 Langues : Anglais (eng) Index. décimale : TA 3.2.2.1 Expérimentation Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7672 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001998 TA 3.2.1 KEN S Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking as a factor in causing lung cancer Type de document : document électronique Auteurs : Peter B. Bach, Auteur ; Jama, Auteur Editeur : American Medical Association (AMA) Année de publication : février 2009 Collection : JAMA Internal Medicine num. 301:5 Importance : p. 359-341 Langues : Anglais (eng) Catégories : [TABAC] étude:épidémiologie
[TABAC] législation:lutte anti-tabac
[TABAC] tabagisme:pathologie:cancer:cancer du poumonIndex. décimale : TA 3.2.2.3 Cancer Résumé : Dans cette étude cas-témoins, les chercheurs ont comparé les antécédents de tabagisme chez les personnes atteintes de cancer du poumon et sans cancer du poumon. Les participants ont été appariés pour leur âge et plusieurs dimensions des antécédents de tabagisme ont été déterminées à l'aide d'un ensemble de questionnaires standardisés (y compris l'âge au début et à la fin du tabac et la quantité moyenne de cigarettes, de cigares ou de pipe fumés par jour). Les antécédents professionnels et les antécédents de maladie pulmonaire antérieure de chaque individu ont été capturés pour contrôler les facteurs de confusion possibles. Les enquêteurs ont découvert que les personnes atteintes d'un cancer du poumon avaient des antécédents de tabagisme plus nombreux que les personnes sans cancer du poumon.
En ligne : https://jama.jamanetwork.com/journals/JAMA/articlepdf/183306/jjc80015_539_541.pd [...] Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8885 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking bans in US hospitals : results of a national survey Type de document : texte imprimé Auteurs : Daniel R. Longo, Auteur ; Ross C. Brownson, Auteur ; Robin L. Kruse, Auteur Editeur : American Medical Association (AMA) Année de publication : 1995 Collection : JAMA : Journal of the American Medical Association num. 274(6) Importance : p.488-491 Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Etats-Unis
[TABAC] législation:législation antitabac:interdiction de fumer
[TABAC] législation:milieu réglementé:hôpitalIndex. décimale : TA 9.3.6.1 Lieux publics Résumé : Objective: To examine compliance and characteristics of hospitals with tobacco control standards enacted by the Joint Commission of Accreditation of Healthcare Organizations (JCAHO).
Design and setting: On-site national survey of hospitals as part of routine JCAHO accreditation visits.
Participants: A total of 3327 US hospitals received site visits in 1992 and 1993 and were matched with American Hospital Association Annual Survey of Hospitals data.
Main outcome measures: Compliance or noncompliance with tobacco control standards; location in a tobacco-producing state; and organizational characteristics, including provision of psychiatric/alcohol-chemical dependency services.
Results: Two years after implementation, 95.6% of hospitals met the new JCAHO smoking ban standard; 90.9% of hospitals were in compliance with a second smoking standard requiring development and use of medical criteria for physician-ordered exceptions to the ban. Hospitals in tobacco-producing states had higher-than-average rates of compliance when compared with hospitals in other states. Hospitals providing psychiatric and/or substance abuse services had lower-than-average rates of compliance.
Conclusion: This first industry-wide smoking ban has been successful. However, hospitals should consider evaluating the use of medical exceptions to this policy.
En ligne : https://pubmed.ncbi.nlm.nih.gov/7629959/ Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9533 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Smoking cessation with varenicline, a selective alpha-4-beta-2 nicotinic receptor partial agonist / Mitchell Nides (2006)
Titre : Smoking cessation with varenicline, a selective alpha-4-beta-2 nicotinic receptor partial agonist : results from a 7-week, randomized, placebo and Bupropion controlled trial with 1 year follow-up Type de document : texte imprimé Auteurs : Mitchell Nides, Auteur ; Cheryl Oncken, Auteur ; David H. Gonzales, Auteur Editeur : American Medical Association (AMA) Année de publication : 2006 Collection : Archives of internal medicine, ISSN 0003-9926 num. Vol 14, n.28 Importance : p. 1561-1568 Présentation : ill., tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Background Currently available smoking cessation therapies have limited success rates. Varenicline tartrate is a novel, selective nicotinic receptor partial agonist developed specifically for smoking cessation. This study evaluated the efficacy, tolerability, and safety of 3 varenicline doses for smoking cessation. Bupropion hydrochloride was included as an active control.
Methods A phase 2, multicenter, randomized, double-blind, placebo-controlled study of healthy smokers (18-65 years old). Subjects were randomized to varenicline tartrate, 0.3 mg once daily (n = 128), 1.0 mg once daily (n = 128), or 1.0 mg twice daily (n = 127), for 6 weeks plus placebo for 1 week; to 150-mg sustained-release bupropion hydrochloride twice daily (n = 128) for 7 weeks; or to placebo (n = 127) for 7 weeks.
Results During the treatment phase, the continuous quit rates for any 4 weeks were significantly higher for varenicline tartrate, 1.0 mg twice daily (48.0%; P<.001) and 1.0 mg once daily (37.3%; P<.001), than for placebo (17.1%). The bupropion rate was 33.3% (P = .002 vs placebo). The carbon monoxide–confirmed continuous quit rates from week 4 to week 52 were significantly higher in the varenicline tartrate, 1.0 mg twice daily, group compared with the placebo group (14.4% vs 4.9%; P = .002). The bupropion rate was 6.3% (P = .60 vs placebo). Discontinuation owing to treatment-emergent adverse events was 15.9% for bupropion, 11.2% to 14.3% for varenicline, and 9.8% for placebo. No dose-related increases occurred in adverse events for varenicline.
Conclusions Varenicline tartrate demonstrated both short-term (1 mg twice daily and 1 mg once daily) and long-term efficacy (1 mg twice daily) vs placebo. Varenicline was well tolerated and may provide a novel therapy to aid smoking cessation.
Cigarette smoking remains the world's leading cause of preventable death,1 contributing to 5 million premature deaths in 2000,2 which is estimated to increase to 10 million by 2020.1 Surveys show that most smokers want to quit,3 but most attempts are unaided, with success rates of only 3% to 5% at 1 year.3 Current pharmacotherapies, such as nicotine replacement therapy (NRT), bupropion hydrochloride, and nortriptyline hydrochloride, have shown moderate success, typically doubling short-term quit rates vs placebo,4- 7 with success at 1 year averaging approximately 7% to 30%, depending on the level of adjunctive behavioral counseling.8,9 Consequently, additional, more efficacious smoking cessation medications are needed.
Varenicline tartrate is a novel, nonnicotine agent developed expressly for smoking cessation. It is a selective nicotinic acetylcholine receptor partial agonist that binds specifically at the α4β2 nicotinic receptor subtype.10 The α4β2 receptor is thought to mediate the rewarding properties of nicotine by modulating the release of dopamine in the nucleus accumbens.11- 13 Cytisine, a plant-derived α4β2 partial agonist used for many years as a smoking cessation aid in eastern Europe,14 provided a structural starting point for the development of the higher-affinity varenicline. The agonist effect of oral varenicline on dopamine release is 35% to 60% of that observed with nicotine,10 theoretically sufficient to attenuate craving and withdrawal without producing its own dependence syndrome. The slower release of dopamine with varenicline compared with smoking would also reduce any potential for abuse.10 Varenicline also has a competitive antagonist effect on nicotine due to a substantially higher affinity for the α4β2 receptor.10 Starting therapy 1 week before the target quit day could potentially lead to at least partial extinction of smoking behavior by blocking the rewarding effects of smoked nicotine.15,16 In addition, the blockade of reward could reduce the chance that a “slip” while still undergoing treatment would lead to a full-blown relapse.
The current study was part of a phase 2 program conducted to select the optimal dose for larger-scale, phase 3 studies. The primary objectives were to assess the efficacy, tolerability, and safety of 3 doses of varenicline administered for 6 weeks. A bupropion arm was included as an active control.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7937 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005478 TA 6.2.3.1.4 NID S Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Trends in current electronic cigarette use among youths by age, sex, and race and ethnicity / Delvon, T. Mattingly (2024)
Titre : Trends in current electronic cigarette use among youths by age, sex, and race and ethnicity Type de document : document électronique Auteurs : Delvon, T. Mattingly, Auteur ; Joy, L. Hart, Auteur Editeur : American Medical Association (AMA) Année de publication : 2024 Collection : JAMA Internal Medicine num. 7:2 Importance : 5 p. Présentation : graph., tab. Langues : Anglais (eng) Catégories : [DIVERS] personne:par âge:jeune
[TABAC] CANDIDATS:e-cigarette
[TABAC] étude
[TABAC] tabagisme:tabagisme actifIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Electronic cigarettes (e-cigarettes) are the most used tobacco products among youths in the US and may facilitate progression into use of more harmful products, such as cigarettes, which are associated with premature morbidity and mortality. Although previous research has characterized youth e-cigarette prevalence, updated descriptive statistics on use trends by key sociodemographic characteristics are needed. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10198 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline, an alpha-4-beta-2(α4β2) nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation / David H. Gonzales (01/06/2006)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline for smoking cessation / Robert C. Klesges (2006)
Titre : Varenicline for smoking cessation : definite promise, but no panacea Type de document : texte imprimé Auteurs : Robert C. Klesges, Auteur ; Karen C. Johnson, Auteur ; Grant Somes, Auteur Editeur : American Medical Association (AMA) Année de publication : 2006 Collection : JAMA Internal Medicine num. Vol 296, n. 1 Importance : p. 94-95 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7943 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005484 TA 6.2.3.1.4 KLE V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !